Aptevo Therapeutics (APVO) Competitors $0.28 +0.03 (+11.90%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends APVO vs. EVFM, CPHI, KTTA, PTPI, MBIO, ARTL, HEPA, SBFM, BCEL, and VRPXShould you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Evofem Biosciences (EVFM), China Pharma (CPHI), Pasithea Therapeutics (KTTA), Petros Pharmaceuticals (PTPI), Mustang Bio (MBIO), Artelo Biosciences (ARTL), Hepion Pharmaceuticals (HEPA), Sunshine Biopharma (SBFM), Atreca (BCEL), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical products" industry. Aptevo Therapeutics vs. Evofem Biosciences China Pharma Pasithea Therapeutics Petros Pharmaceuticals Mustang Bio Artelo Biosciences Hepion Pharmaceuticals Sunshine Biopharma Atreca Virpax Pharmaceuticals Aptevo Therapeutics (NASDAQ:APVO) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Which has preferable earnings & valuation, APVO or EVFM? Evofem Biosciences has higher revenue and earnings than Aptevo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptevo Therapeutics$3.11M0.83-$17.41MN/AN/AEvofem Biosciences$11.39M0.13$52.98M-$0.50-0.03 Which has more risk and volatility, APVO or EVFM? Aptevo Therapeutics has a beta of 5.07, indicating that its share price is 407% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -0.79, indicating that its share price is 179% less volatile than the S&P 500. Do insiders & institutionals believe in APVO or EVFM? 8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 0.1% of Aptevo Therapeutics shares are held by company insiders. Comparatively, 0.2% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor APVO or EVFM? In the previous week, Aptevo Therapeutics and Aptevo Therapeutics both had 1 articles in the media. Evofem Biosciences' average media sentiment score of 0.88 beat Aptevo Therapeutics' score of 0.28 indicating that Evofem Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptevo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evofem Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is APVO or EVFM more profitable? Evofem Biosciences has a net margin of 341.16% compared to Aptevo Therapeutics' net margin of 0.00%. Evofem Biosciences' return on equity of -91.97% beat Aptevo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aptevo TherapeuticsN/A -269.26% -119.48% Evofem Biosciences 341.16%-91.97%594.75% Do analysts recommend APVO or EVFM? Aptevo Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 2,826.12%. Given Aptevo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aptevo Therapeutics is more favorable than Evofem Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Evofem Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community believe in APVO or EVFM? Evofem Biosciences received 63 more outperform votes than Aptevo Therapeutics when rated by MarketBeat users. Likewise, 69.50% of users gave Evofem Biosciences an outperform vote while only 50.77% of users gave Aptevo Therapeutics an outperform vote. CompanyUnderperformOutperformAptevo TherapeuticsOutperform Votes19950.77% Underperform Votes19349.23% Evofem BiosciencesOutperform Votes26269.50% Underperform Votes11530.50% SummaryEvofem Biosciences beats Aptevo Therapeutics on 9 of the 15 factors compared between the two stocks. Ad Porter & CompanyThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APVO vs. The Competition Export to ExcelMetricAptevo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.57M$6.75B$5.02B$8.42BDividend YieldN/A7.94%7.49%4.16%P/E RatioN/A11.78128.4816.64Price / Sales0.83288.471,723.1677.30Price / CashN/A46.0936.9033.53Price / Book0.015.284.595.19Net Income-$17.41M$150.82M$113.94M$223.67M7 Day Performance14.94%-0.69%110.64%2.76%1 Month Performance61.50%15.56%124.65%8.82%1 Year Performance-97.61%37.06%155.07%29.33% Aptevo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APVOAptevo Therapeutics2.6572 of 5 stars$0.28+11.9%$8.00+2,736.9%-97.8%$2.66M$3.11M0.0050EVFMEvofem Biosciences0.7724 of 5 stars$0.01flatN/A-80.6%$1.06M$18.22M-0.02120Gap DownCPHIChina PharmaN/A$0.24+4.3%N/A-46.1%$3.88M$7.78M0.00250KTTAPasithea TherapeuticsN/A$3.69-0.3%N/A-47.2%$3.85M$20,000.000.003Upcoming EarningsPTPIPetros Pharmaceuticals3.2653 of 5 stars$0.40-2.4%$4.00+903.0%-75.9%$3.83M$5.82M-0.0620MBIOMustang Bio1.9101 of 5 stars$0.30+3.4%$2.00+562.3%-84.6%$3.78MN/A-0.11100News CoverageGap DownARTLArtelo Biosciences2.9365 of 5 stars$1.14-2.6%$5.00+338.6%-13.5%$3.68MN/A-0.345Upcoming EarningsHEPAHepion Pharmaceuticals0.539 of 5 stars$0.66-5.7%N/A-84.7%$3.61MN/A-0.1020Gap DownSBFMSunshine Biopharma1.0551 of 5 stars$2.95-2.3%N/A-90.2%$3.60M$24.09M-0.013Upcoming EarningsBCELAtrecaN/A$0.09flatN/AN/A$3.57MN/A-0.04130VRPXVirpax Pharmaceuticals1.1339 of 5 stars$0.72+16.1%$3.00+316.7%-89.9%$3.52MN/A0.007Gap Up Related Companies and Tools Related Companies EVFM Alternatives CPHI Alternatives KTTA Alternatives PTPI Alternatives MBIO Alternatives ARTL Alternatives HEPA Alternatives SBFM Alternatives BCEL Alternatives VRPX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APVO) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
